A benefit–harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions

Wendy Bennett, Hélène E. Aschmann, Milo A. Puhan, Craig W. Robbins, Elizabeth A. Bayliss, Renee Wilson, Richard A. Mularski, Wiley V. Chan, Bruce A Leff, Orla Sheehan, Carol Glover, Katie Maslow, Karen Armacost, Suzanne Mintz, Cynthia Boyd

Research output: Contribution to journalArticle

Abstract

Objectives: The benefits and harms of diabetes treatments need to be carefully weighed in people with type II diabetes mellitus (DM) and multiple chronic conditions (MCCs). Our objective was to quantitatively assess the benefits and harms of the addition of basal insulin (insulin) vs. sulfonylurea (SU) to metformin in people with DM and MCCs. Study Design and Setting: Data inputs into the benefit–harms analysis included (1) baseline risks of patient-centered outcomes (death, myocardial infarction, stroke, severe hypoglycemia, diarrhea, nausea) from cohorts and trials; (2) treatment effects for the addition of insulin vs. SU from a network meta-analysis; and (3) patient preference survey for outcome weights. Statistical analysis calculated the probability that adding insulin has greater benefits than harms, when compared with an SU, overall and by prespecified subgroups. Results: Including the six outcomes, the probability of net benefit for insulin compared with SU was similar, across subgroups by age and diabetes duration (probability range, using conditional logit weights: 0.44–0.56). Adding patient preferences for treatment burden associated with insulin injections shifted the probability to favor SU over insulin (probability range, using conditional logit weights: 0.01–0.12). Conclusion: In people with DM and MCCs, we demonstrated incomplete evidence to conclude if basal insulin or SU should be added in people with DM and MCCs on metformin alone. The benefit–harm balance was sensitive to treatment preferences, that is., perceived treatment burden, indicating the importance of shared-decision making in caring for people with MCCs who are at high risk for experiencing harms associated with diabetes management.

Original languageEnglish (US)
Pages (from-to)92-100
Number of pages9
JournalJournal of Clinical Epidemiology
Volume113
DOIs
StatePublished - Sep 1 2019

Fingerprint

Metformin
Type 2 Diabetes Mellitus
Insulin
Diabetes Mellitus
Patient Preference
Weights and Measures
Therapeutics
Multiple Chronic Conditions
Hypoglycemia
Nausea
Diarrhea
Decision Making
Stroke
Myocardial Infarction
Injections

Keywords

  • Diabetes/complications
  • Diabetes/treatment
  • Multiple chronic conditions
  • Older adults
  • Patient preferences
  • Risk assessment/methods

ASJC Scopus subject areas

  • Epidemiology

Cite this

A benefit–harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions. / Bennett, Wendy; Aschmann, Hélène E.; Puhan, Milo A.; Robbins, Craig W.; Bayliss, Elizabeth A.; Wilson, Renee; Mularski, Richard A.; Chan, Wiley V.; Leff, Bruce A; Sheehan, Orla; Glover, Carol; Maslow, Katie; Armacost, Karen; Mintz, Suzanne; Boyd, Cynthia.

In: Journal of Clinical Epidemiology, Vol. 113, 01.09.2019, p. 92-100.

Research output: Contribution to journalArticle

Bennett, Wendy ; Aschmann, Hélène E. ; Puhan, Milo A. ; Robbins, Craig W. ; Bayliss, Elizabeth A. ; Wilson, Renee ; Mularski, Richard A. ; Chan, Wiley V. ; Leff, Bruce A ; Sheehan, Orla ; Glover, Carol ; Maslow, Katie ; Armacost, Karen ; Mintz, Suzanne ; Boyd, Cynthia. / A benefit–harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions. In: Journal of Clinical Epidemiology. 2019 ; Vol. 113. pp. 92-100.
@article{6328e49c1dea42dcb74b95b17fc9feb4,
title = "A benefit–harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions",
abstract = "Objectives: The benefits and harms of diabetes treatments need to be carefully weighed in people with type II diabetes mellitus (DM) and multiple chronic conditions (MCCs). Our objective was to quantitatively assess the benefits and harms of the addition of basal insulin (insulin) vs. sulfonylurea (SU) to metformin in people with DM and MCCs. Study Design and Setting: Data inputs into the benefit–harms analysis included (1) baseline risks of patient-centered outcomes (death, myocardial infarction, stroke, severe hypoglycemia, diarrhea, nausea) from cohorts and trials; (2) treatment effects for the addition of insulin vs. SU from a network meta-analysis; and (3) patient preference survey for outcome weights. Statistical analysis calculated the probability that adding insulin has greater benefits than harms, when compared with an SU, overall and by prespecified subgroups. Results: Including the six outcomes, the probability of net benefit for insulin compared with SU was similar, across subgroups by age and diabetes duration (probability range, using conditional logit weights: 0.44–0.56). Adding patient preferences for treatment burden associated with insulin injections shifted the probability to favor SU over insulin (probability range, using conditional logit weights: 0.01–0.12). Conclusion: In people with DM and MCCs, we demonstrated incomplete evidence to conclude if basal insulin or SU should be added in people with DM and MCCs on metformin alone. The benefit–harm balance was sensitive to treatment preferences, that is., perceived treatment burden, indicating the importance of shared-decision making in caring for people with MCCs who are at high risk for experiencing harms associated with diabetes management.",
keywords = "Diabetes/complications, Diabetes/treatment, Multiple chronic conditions, Older adults, Patient preferences, Risk assessment/methods",
author = "Wendy Bennett and Aschmann, {H{\'e}l{\`e}ne E.} and Puhan, {Milo A.} and Robbins, {Craig W.} and Bayliss, {Elizabeth A.} and Renee Wilson and Mularski, {Richard A.} and Chan, {Wiley V.} and Leff, {Bruce A} and Orla Sheehan and Carol Glover and Katie Maslow and Karen Armacost and Suzanne Mintz and Cynthia Boyd",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.jclinepi.2019.03.014",
language = "English (US)",
volume = "113",
pages = "92--100",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - A benefit–harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions

AU - Bennett, Wendy

AU - Aschmann, Hélène E.

AU - Puhan, Milo A.

AU - Robbins, Craig W.

AU - Bayliss, Elizabeth A.

AU - Wilson, Renee

AU - Mularski, Richard A.

AU - Chan, Wiley V.

AU - Leff, Bruce A

AU - Sheehan, Orla

AU - Glover, Carol

AU - Maslow, Katie

AU - Armacost, Karen

AU - Mintz, Suzanne

AU - Boyd, Cynthia

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Objectives: The benefits and harms of diabetes treatments need to be carefully weighed in people with type II diabetes mellitus (DM) and multiple chronic conditions (MCCs). Our objective was to quantitatively assess the benefits and harms of the addition of basal insulin (insulin) vs. sulfonylurea (SU) to metformin in people with DM and MCCs. Study Design and Setting: Data inputs into the benefit–harms analysis included (1) baseline risks of patient-centered outcomes (death, myocardial infarction, stroke, severe hypoglycemia, diarrhea, nausea) from cohorts and trials; (2) treatment effects for the addition of insulin vs. SU from a network meta-analysis; and (3) patient preference survey for outcome weights. Statistical analysis calculated the probability that adding insulin has greater benefits than harms, when compared with an SU, overall and by prespecified subgroups. Results: Including the six outcomes, the probability of net benefit for insulin compared with SU was similar, across subgroups by age and diabetes duration (probability range, using conditional logit weights: 0.44–0.56). Adding patient preferences for treatment burden associated with insulin injections shifted the probability to favor SU over insulin (probability range, using conditional logit weights: 0.01–0.12). Conclusion: In people with DM and MCCs, we demonstrated incomplete evidence to conclude if basal insulin or SU should be added in people with DM and MCCs on metformin alone. The benefit–harm balance was sensitive to treatment preferences, that is., perceived treatment burden, indicating the importance of shared-decision making in caring for people with MCCs who are at high risk for experiencing harms associated with diabetes management.

AB - Objectives: The benefits and harms of diabetes treatments need to be carefully weighed in people with type II diabetes mellitus (DM) and multiple chronic conditions (MCCs). Our objective was to quantitatively assess the benefits and harms of the addition of basal insulin (insulin) vs. sulfonylurea (SU) to metformin in people with DM and MCCs. Study Design and Setting: Data inputs into the benefit–harms analysis included (1) baseline risks of patient-centered outcomes (death, myocardial infarction, stroke, severe hypoglycemia, diarrhea, nausea) from cohorts and trials; (2) treatment effects for the addition of insulin vs. SU from a network meta-analysis; and (3) patient preference survey for outcome weights. Statistical analysis calculated the probability that adding insulin has greater benefits than harms, when compared with an SU, overall and by prespecified subgroups. Results: Including the six outcomes, the probability of net benefit for insulin compared with SU was similar, across subgroups by age and diabetes duration (probability range, using conditional logit weights: 0.44–0.56). Adding patient preferences for treatment burden associated with insulin injections shifted the probability to favor SU over insulin (probability range, using conditional logit weights: 0.01–0.12). Conclusion: In people with DM and MCCs, we demonstrated incomplete evidence to conclude if basal insulin or SU should be added in people with DM and MCCs on metformin alone. The benefit–harm balance was sensitive to treatment preferences, that is., perceived treatment burden, indicating the importance of shared-decision making in caring for people with MCCs who are at high risk for experiencing harms associated with diabetes management.

KW - Diabetes/complications

KW - Diabetes/treatment

KW - Multiple chronic conditions

KW - Older adults

KW - Patient preferences

KW - Risk assessment/methods

UR - http://www.scopus.com/inward/record.url?scp=85067401878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067401878&partnerID=8YFLogxK

U2 - 10.1016/j.jclinepi.2019.03.014

DO - 10.1016/j.jclinepi.2019.03.014

M3 - Article

VL - 113

SP - 92

EP - 100

JO - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

SN - 0895-4356

ER -